CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • NUNZ Dashboard
  • Financials
  • Filings
  • 8-K Filing

NUNZIA PHARMACEUTICAL (NUNZ) 8-KEntry into a Material Definitive Agreement

Filed: 17 Aug 21, 7:38am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • Download Excel data file
    • View Excel data file
    NUNZ similar filings
    • 18 Mar 22 Entry into a Material Definitive Agreement
    • 2 Mar 22 Entry into a Material Definitive Agreement
    • 17 Aug 21 Entry into a Material Definitive Agreement
    • 4 Aug 21 Entry into a Material Definitive Agreement
    • 7 May 21 Entry into a Material Definitive Agreement
    • 31 Mar 20 Other Events
    Filing view
    Share this filing

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report: August 16, 2021

    (Date of earliest event reported)

     

    Commission File Number: 001-39175

     

    NUNZIA PHARMACEUTICAL COMPANY

    (Exact name of registrant as specified in its charter)

     

     

    Utah

    (State or other jurisdiction of incorporation or organization)

    87-0442090

    (I.R.S. Employer Identification No.)

     

     

    1627 West 14th Street, Long Beach, California

     

     

    90813

    (Address of principal executive offices)

    (Zip Code)

     

    (714) 609 9117

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name, former address and former fiscal year)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    1


     

    Section 1 - Registrant’s Business and Operations

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On June 9, 2021 GoCloud through there JV Partnership with the suppliers and authorized distributor issued an email authorizing NUNZIA Pharmaceutical to sell the following vaccines: J&J, AZ, Pfizer, Moderna and Sputnick.

     

    I have attached the email below.


    2


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    NUNZIA PHARMACEUTICAL COMPANY

     

     

     

     

     

     

     

    By: /s/ Michael Mitsunaga

     

    Michael Mitsunaga

    President

     

     

     

    Dated: August 16, 2021


    3


     

     

    Exhibit

     

    Umashankar Das <dr.udas999@gmail.com>

    Jun 9, 2021, 3:41 PM

     

     

     

     

    Hi Michael,

    It was nice talking to you. As discussed with you we have good access to covid vaccines through our JV partnership with the supplier and authorized distributor. Gocloud will sell to Nunzia the following vaccines: J&J, AZ, Pfizer, Moderna and Sputnik. 

     

    Please let us know your requirements. We look forward to working with you to fulfil your orders.

     

    Thank you.

     

    Dr. Umashankar Das, Ph.D., M.B.A.

    President & CEO

    Gocloud Technologies Inc.


    4

     

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn